June 22 (NBD) -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced Friday that its subsidary Shanghai Henlius Biotech, Inc. (Shanghai Henlius) has granted Accord Healthcare Limited (Accord) a series of rights including the exclusive commercialization right for Henlius' Recombinant Humanized Anti-Her2 Monoclonal Antibody  Injection (HLX02) in designated regions (Europe, some parts of Middle East and North Africa, and some Commonwealth of Independent States countries).

The  Trastuzumab biosimilar is for treatment of breast cancer and now is in the phrase III clinical trails in mainland China, Ukraine, Poland, and some other countries.   

New drugs development entails risks and might be ended in clinical tests due to security and efficacy concerns. The R&D, registration, manufacture and distribution of the drug in above designated regions is still subject to the approval of local regulatory bodies, including but not limited to the European Medicines Agency. 

Data from the world's leading healthcare reference data provider IQVIA's analytics platform MIDAS shows that the global sales of original trastuzumab drug Herceptin stood at 5.87 billion U.S. dollars last year.

Email: tanyuhan@nbd.com.cn